<?xml version="1.0" ?>
<!DOCTYPE pmc-articleset PUBLIC "-//NLM//DTD ARTICLE SET 2.0//EN" "https://dtd.nlm.nih.gov/ncbi/pmc/articleset/nlm-articleset-2.0.dtd">
<pmc-articleset><article xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" article-type="case-report">
  <?properties open_access?>
  <front>
    <journal-meta>
      <journal-id journal-id-type="nlm-ta">Rev Inst Med Trop Sao Paulo</journal-id>
      <journal-id journal-id-type="iso-abbrev">Rev. Inst. Med. Trop. Sao Paulo</journal-id>
      <journal-title-group>
        <journal-title>Revista do Instituto de Medicina Tropical de S&#xE3;o Paulo</journal-title>
      </journal-title-group>
      <issn pub-type="ppub">0036-4665</issn>
      <issn pub-type="epub">1678-9946</issn>
      <publisher>
        <publisher-name>Instituto de Medicina Tropical</publisher-name>
      </publisher>
    </journal-meta>
    <article-meta>
      <article-id pub-id-type="pmid">25229226</article-id>
      <article-id pub-id-type="pmc">4172117</article-id>
      <article-id pub-id-type="publisher-id">S0036-46652014000500012</article-id>
      <article-id pub-id-type="doi">10.1590/S0036-46652014000500012</article-id>
      <article-categories>
        <subj-group subj-group-type="heading">
          <subject>Case Report</subject>
        </subj-group>
      </article-categories>
      <title-group>
        <article-title>FIRST REPORT ON OTOTOXICITY OF MEGLUMINE
ANTIMONIATE</article-title>
        <trans-title-group xml:lang="pt">
          <trans-title>Primeiro relato de ototoxicidade pelo antimoniato de
meglumina</trans-title>
        </trans-title-group>
      </title-group>
      <contrib-group>
        <contrib contrib-type="author">
          <name>
            <surname>Valete-Rosalino</surname>
            <given-names>Cl&#xE1;udia Maria</given-names>
          </name>
          <xref ref-type="aff" rid="aff1">
<sup>(1)</sup>
</xref>
          <xref ref-type="aff" rid="aff2">
<sup>(2)</sup>
</xref>
        </contrib>
        <contrib contrib-type="author">
          <name>
            <surname>Araujo-Melo</surname>
            <given-names>Maria Helena</given-names>
          </name>
          <xref ref-type="aff" rid="aff1">
<sup>(1)</sup>
</xref>
          <xref ref-type="aff" rid="aff3">
<sup>(3)</sup>
</xref>
        </contrib>
        <contrib contrib-type="author">
          <name>
            <surname>Bezerra</surname>
            <given-names>D&#xE9;bora Cristina de Oliveira</given-names>
          </name>
          <xref ref-type="aff" rid="aff2">
<sup>(2)</sup>
</xref>
        </contrib>
        <contrib contrib-type="author">
          <name>
            <surname>de Barcelos</surname>
            <given-names>Renata Oliveira</given-names>
          </name>
          <xref ref-type="aff" rid="aff2">
<sup>(2)</sup>
</xref>
        </contrib>
        <contrib contrib-type="author">
          <name>
            <surname>de Melo-Ferreira</surname>
            <given-names>Vanessa</given-names>
          </name>
          <xref ref-type="aff" rid="aff1">
<sup>(1)</sup>
</xref>
          <xref ref-type="aff" rid="aff2">
<sup>(2)</sup>
</xref>
          <xref ref-type="aff" rid="aff4">
<sup>(4)</sup>
</xref>
        </contrib>
        <contrib contrib-type="author">
          <name>
            <surname>Torraca</surname>
            <given-names>T&#xE2;nia Salgado de Sousa</given-names>
          </name>
          <xref ref-type="aff" rid="aff1">
<sup>(1)</sup>
</xref>
          <xref ref-type="aff" rid="aff2">
<sup>(2)</sup>
</xref>
        </contrib>
        <contrib contrib-type="author">
          <name>
            <surname>Martins</surname>
            <given-names>Ana Cristina da Costa</given-names>
          </name>
          <xref ref-type="aff" rid="aff1">
<sup>(1)</sup>
</xref>
        </contrib>
        <contrib contrib-type="author">
          <name>
            <surname>Moreira</surname>
            <given-names>Jo&#xE3;o Soares</given-names>
          </name>
          <xref ref-type="aff" rid="aff1">
<sup>(1)</sup>
</xref>
        </contrib>
        <contrib contrib-type="author">
          <name>
            <surname>Vargas</surname>
            <given-names>Mirian Catherine Melgares</given-names>
          </name>
          <xref ref-type="aff" rid="aff1">
<sup>(1)</sup>
</xref>
        </contrib>
        <contrib contrib-type="author">
          <name>
            <surname>Braga</surname>
            <given-names>Frederico Pereira Bom</given-names>
          </name>
          <xref ref-type="aff" rid="aff1">
<sup>(1)</sup>
</xref>
        </contrib>
        <contrib contrib-type="author">
          <name>
            <surname>Salgueiro</surname>
            <given-names>Mariza de Matos</given-names>
          </name>
          <xref ref-type="aff" rid="aff1">
<sup>(1)</sup>
</xref>
        </contrib>
        <contrib contrib-type="author">
          <name>
            <surname>Saheki</surname>
            <given-names>Maur&#xED;cio Naoto</given-names>
          </name>
          <xref ref-type="aff" rid="aff1">
<sup>(1)</sup>
</xref>
        </contrib>
        <contrib contrib-type="author">
          <name>
            <surname>Schubach</surname>
            <given-names>Armando Oliveira</given-names>
          </name>
          <xref ref-type="aff" rid="aff1">
<sup>(1)</sup>
</xref>
          <xref ref-type="aff" rid="aff5">
<sup>(5)</sup>
</xref>
        </contrib>
        <aff id="aff1"><label>(1)</label>
Funda&#xE7;&#xE3;o Oswaldo Cruz
(IPEC-FIOCRUZ), Rio de Janeiro, RJ, Brazil, Instituto de Pesquisa C&#xED;nica Evandro
Chagas, Funda&#xE7;&#xE3;o Oswaldo Cruz (IPEC-FIOCRUZ), Rio de
Janeiro, RJ, Brazil</aff>
        <aff id="aff2"><label>(2)</label>
Departamento de Otorrino e
Oftalmologia, Universidade Federal do Rio de Janeiro
(UFRJ), Rio de Janeiro, RJ, Brazil, Departamento de Otorrino e Oftalmologia,
Universidade Federal do Rio de Janeiro (UFRJ), Rio de Janeiro, RJ,
Brazil</aff>
        <aff id="aff3"><label>(3)</label>
Universidade Federal do Estado do Rio de
Janeiro (UNIRIO), Rio de Janeiro, RJ, Brazil, Universidade Federal do Estado do Rio de
Janeiro (UNIRIO), Rio de Janeiro, RJ, Brazil</aff>
        <aff id="aff4"><label>(4)</label>
Funda&#xE7;&#xE3;o de Amparo &#xE0; Pesquisa
do Estado do Rio de Janeiro (FAPERJ), Bolsista de inicia&#xE7;&#xE3;o
cient&#xED;fica, Rio de Janeiro, RJ, Brazil, Funda&#xE7;&#xE3;o de Amparo &#xE0;
Pesquisa do Estado do Rio de Janeiro (FAPERJ), Bolsista de
inicia&#xE7;&#xE3;o cient&#xED;fica, Rio de Janeiro, RJ,
Brazil</aff>
        <aff id="aff5"><label>(5)</label>
Conselho Nacional de Desenvolvimento
Cient&#xED;fico e Tecnol&#xF3;gico (CNPq)</aff>
      </contrib-group>
      <author-notes>
        <corresp><bold>Correspondence to:</bold> Cl&#xE1;udia Maria Valete-Rosalino, Av.
Brasil 4365, 21040-360 Rio de Janeiro, RJ, Brasil. Tel: <phone>55+21
38659541</phone>. E-mail: <email>claudia.valete@ipec.fiocruz.br</email></corresp>
        <fn fn-type="conflict">
          <p>The authors state no conflict of interest.</p>
        </fn>
        <fn fn-type="com">
          <p>Cl&#xE1;udia Maria Valete-Rosalino has full access to all the data in the study
and takes responsibility for their integrity.</p>
        </fn>
      </author-notes>
      <pub-date pub-type="epub-ppub">
        <season>Sep-Oct</season>
        <year>2014</year>
      </pub-date>
      <!--Fake ppub date generated by PMC from publisher
							pub-date/@pub-type='epub-ppub' -->
      <pub-date pub-type="ppub">
        <season>Sep-Oct</season>
        <year>2014</year>
      </pub-date>
      <volume>56</volume>
      <issue>5</issue>
      <fpage>439</fpage>
      <lpage>442</lpage>
      <history>
        <date date-type="received">
          <day>7</day>
          <month>8</month>
          <year>2013</year>
        </date>
        <date date-type="accepted">
          <day>27</day>
          <month>2</month>
          <year>2014</year>
        </date>
      </history>
      <permissions>
        <license license-type="open-access" xlink:href="http://creativecommons.org/licenses/by-nc/3.0/">
          <license-p>This is an Open Access article distributed under the terms of the
Creative Commons Attribution Non-Commercial License, which permits
unrestricted non-commercial use, distribution, and reproduction in any
medium, provided the original work is properly cited.</license-p>
        </license>
      </permissions>
      <abstract>
        <p id="para1">
<bold>Introduction:</bold> Pentavalent antimonials are the first drug
of choice in the treatment of tegumentary leishmaniasis. Data on ototoxicity
related with such drugs is scarcely available in literature, leading us to
develop a study on cochleovestibular functions.</p>
        <p id="para2">
<bold>Case Report:</bold> A case of a tegumentary leishmaniasis
patient, a 78-year-old man who presented a substantial increase in auditory
threshold with tinnitus and severe rotatory dizziness during the treatment with
meglumine antimoniate, is reported. These symptoms worsened in two weeks after
treatment was interrupted.</p>
        <p id="para3">
<bold>Conclusion:</bold> Dizziness and tinnitus had already been
related to meglumine antimoniate. However, this is the first well documented
case of cochlear-vestibular toxicity related to meglumine antimoniate.</p>
      </abstract>
      <trans-abstract xml:lang="pt">
        <p id="para4">
<bold>Introdu&#xE7;&#xE3;o:</bold> Antimoniais pentavalentes s&#xE3;o
os f&#xE1;rmacos de primeira escolha no tratamento da leishmaniose tegumentar.
Dados de ototoxicidade relacionados a tais f&#xE1;rmacos s&#xE3;o escassos na
literatura, o que nos levou a desenvolver um estudo de fun&#xE7;&#xF5;es
c&#xF3;cleo-vestibulares.</p>
        <p id="para5">
<bold>Relato de caso:</bold> Relatamos caso de paciente masculino de
78 anos com leishmaniose tegumentar, que apresentou aumento significativo dos
limiares auditivos com zumbido e tontura rotat&#xF3;ria grave durante o
tratamento com antimoniato de meglumina. Os sintomas pioraram at&#xE9; duas
semanas ap&#xF3;s a interrup&#xE7;&#xE3;o do tratamento.</p>
        <p id="para6">
<bold>Conclus&#xE3;o:</bold> Tontura e zumbido j&#xE1; tinham sido
associados ao antimoniato de meglumina. Entretanto, este &#xE9; o primeiro caso
bem documentado de toxicidade c&#xF3;cleo-vestibular relacionado ao antimoniato
de meglumina.</p>
      </trans-abstract>
      <kwd-group>
        <kwd>Mucocutaneous Leishmaniasis</kwd>
        <kwd>Drug Toxicity</kwd>
        <kwd>Meglumine antimoniate</kwd>
        <kwd>Hearing loss</kwd>
        <kwd>Tinnitus</kwd>
        <kwd>Dizziness</kwd>
      </kwd-group>
      <counts>
        <fig-count count="2"/>
        <table-count count="0"/>
        <ref-count count="19"/>
        <page-count count="4"/>
      </counts>
    </article-meta>
  </front>
  <body>
    <sec sec-type="intro">
      <title>INTRODUCTION</title>
      <p id="para7">Pentavalent antimonials are still the first drug of choice in the
treatment of tegumentary leishmaniasis (TL), although they can cause
adverse reactions such as electrocardiographic, liver, pancreas and kidney function
alterations<sup><xref rid="B04" ref-type="bibr">4</xref></sup>. Myalgia,
arthralgia and fever are common and vestibular alterations such as dizziness are
occasionally observed<sup><xref rid="B02" ref-type="bibr">2</xref>,<xref rid="B12" ref-type="bibr">12</xref></sup>. However, we could not find any
well documented report on cochlear and vestibular toxicity caused by meglumine
antimoniate.</p>
      <p id="para8">The present case report of ototoxicity of meglumine antimoniate
(MA) was diagnosed during an ongoing longitudinal study in patients with
TL treated at IPEC-FIOCRUZ, Rio de Janeiro, Brazil. All patients were submitted to
vestibular evaluation (Vectoelectronystagmography - VENG) and audiologic
evaluation (conventional pure tone audiometry, distortion product otoacoustic
emissions - DPOAE and tympanogram) before, during (every ten days)
and up to three months after treatment discontinuation or normalization of
alterations. During the monitoring process, patients were submitted to physical
examination, blood biochemistry, complete blood count and ECG. The normal values of
the laboratory tests were: glucose (70-110 mg/dL); urea (15-38
mg/dL); creatinine (0.6-1.3 mg/dL); amylase (25-115
mg/dL); lypase (114-286 mg/dL); (aspartate
transaminase (AST) (15-37 U/L); alanine transaminase
(ALT) (12-78 U/L); alkaline phosphatase (ALP)
(50-136 U/L); gamma glutamyl transpeptidase (GGT) 15-85
U/L.</p>
      <p id="para9">Ototoxicity was considered the onset of dizziness and/or hearing loss
(with a unilateral or bilateral audiometric threshold increase equal to or
greater than 20 dB, at one or more frequencies, or a 10dB increase at two adjacent
frequencies) during treatment with meglumine antimoniate<sup><xref rid="B01" ref-type="bibr">1</xref>,<xref rid="B06" ref-type="bibr">6</xref></sup>.</p>
      <p id="para10">This study was submitted to and approved by the Research on Human Beings
Ethics Committee of the Evandro Chagas Research Institute of the Oswaldo Cruz
Foundation (IPEC- FIOCRUZ), under the number 0055.0.009.000-07. The
patient agreed to participate in the study and signed a free informed consent
form.</p>
    </sec>
    <sec>
      <title>CASE REPORT</title>
      <p id="para11">A seventy-eight year-old man, without previous skin lesions or skin scars
consistent with tegumentary leishmaniasis (TL), evolved during the last
year with volume increase in the nasal pyramid to the right side, nasal obstruction,
epistaxis to manipulation of nasal cavities, crusting and occasional cacosmia. He
also had 117 mg/dL glucose; 48 mg/dL urea; 1.5 mg/dL creatinine; 78
mg/dL amylase; 22 U/L AST; 30 U/L ALT; 74 U/L ALP. Systemic
arterial hypertension was treated with 25 mg/day hydrochlorothiazide 20
mg/day nifedipine, 2 mg/day doxazosin mesylate, besides 50 mg SOS sodium
diclofenac, due to chronic muscle pain. He reported bilateral hearing loss for the
last seven years, but he denied tinnitus, dizziness, noise exposure or family
history of auditory and/or vestibular symptoms. Otoscopy was normal and the
endoscopic examination of the upper aero-digestive tract presented infiltration of
the right nasal wing and the entire mucosa of the right nasal cavity, preventing
progression of optics. There was also infiltration of the vestibular region,
anterior nasal septum and head of the left inferior turbinate, with discrete crusts,
as well as absence of mucosal lesions in the pharynx and larynx. Syphilis and fungal
serologies were negative. TL serologies performed were: 1:40 indirect
immunofluorescence technique and ELISA reactor. A nasal biopsy was performed.
Fragment cultures were negative to <italic>Leishmania</italic>, mycobacteria and
fungus. The histopathological examination revealed chronic granulomatous
inflammation with necrosis. The immunohistochemistry with
anti-<italic>Leishmania</italic> serum showed occasional amastigote forms and
polymerase chain reaction was positive to <italic>Leishmania</italic>. A
pre-treatment audiometric study showed mild to severe sensorineural hearing loss,
tritone mean at 500-1000-2000 Hz of 53dB and 62dB, in the right and left ears,
respectively. Additionally, he presented bilateral type A tympanogram and
bilaterally absent distortion product otoacoustic emissions (DPOAE).
Treatment with meglumine antimoniate (MA) (Glucantime&#xAE; from
Sanofi Aventis) was initiated at a maximum daily dose of three ampoules
(weight 72 kg; dose 16.9 mgSb<sup>+5</sup>/kg/day) for 30
days.</p>
      <p id="para12">On the twelfth day of treatment, the patient returned with herpes zoster
in the buttock (dermatome S1) and myalgia, and acyclovir cream, urea cream
and 50 mg of sodium diclofenac if pain were prescribed. He was asymptomatic from the
cochlea-vestibular point of view, but presented a 10 dB increase of the auditory
threshold at 6 kHz and a 15 dB increase at 8 kHz in the left ear (LE). On
the twenty-sixth day, treatment was discontinued due to cutaneous rash, scaling of
lower limbs, difficulty in walking, arthralgia, myalgia, hand tremor, dry oral
mucosa, anorexia and loss of weight (-3 kg). He also presented frequent
severe rotatory dizziness lasting some minutes with no associated vagal symptoms,
without worsening of hearing complaints previously reported. VENG was normal and the
audiometry showed a 20 dB increase at 6 KHz and a 25 dB increase at 8 KHz in the LE.
He also had 153 mg/dL glucose; 83 mg/dL urea; 322 mg/dL amylase; 181
U/L AST; 174 U/L ALT; 112 U/L ALP; 175 U/L GGT) and QTc
0.46. Sixteen days after the treatment was discontinued, he maintained rare
non-rotatory dizziness lasting seconds, without objective worsening of hearing
complaints, but with tinnitus, and he had fallen two days before. Pure tone
audiometry presented severe worsening of LE auditory thresholds (10 dB increase
at 250 Hz; 10 dB increase at 500 Hz; 15 dB increase at 1 KHz; 25 dB increase at 2
KHz; 30 dB increase at 3 KHz; 15 dB increase at 6 KHz; and 45 dB increase at 8
KHz) and VENG was within the normal range, although with reduction of more than
50% of the previous value of Angular Velocity of the Slow Component of
Nystagmus in degrees per second (AVSC&#xB0;/s) at 18 &#xB0;C. He had
118 mg/dL glucose; 30 mg/dL urea; 90 mg/dL amylase; 41 U/L AST;
71 U/L ALT; 155 U/L ALP; 128 U/L GGT) and QTc 0.33. Twenty-eight
days after treatment interruption, he no longer had tinnitus and dizziness remained
of mild intensity and lasting seconds. He walked adequately and myalgia and tremors
had improved. Pure audiometry showed no more increments consistent with ototoxicity
criterion. He had 110 mg/dL glucose; 1.4 mg/dL creatinine; 105 mg/dL
amylase; 371 mg/dL lypase; 34 U/L AST; 43 U/L ALT; 115 U/L ALP;
80 U/L GGT) and QTc 0.33. As the patient still presented mucosa lesions 90
days after treatment interruption, he was successfully treated with 150 mg/day
(2.2 mg/kg/day) liposomal amphotericin B, up to an accumulated
dose of 1800 mg, when it was discontinued due to serum creatinine value of 1.6
mg/dL, without worsening of hearing and/or dizziness complaints. A year
and four months later, he did not present worsening of hearing complaints when
compared to the beginning of treatment with MA, neither tinnitus nor dizziness, and
the audiometry was not consistent with ototoxicity criterion and VENG was within the
normal range, with AVSC in the LE at 18 &#xB0;C returning to values similar to the
beginning of symptomatology. The DPOAE examination remained absent during the entire
monitoring. <xref ref-type="fig" rid="f01">Graphs 1</xref>
<xref ref-type="fig" rid="f02"/> (Pure tone audiometry through air conduction of the left ear of
a patient during the monitoring process, IPEC, FioCruz, Rio de Janeiro, 2011)
and 2 (Variations of Angular Velocity of the Slow Component of Nystagmus in
degrees per second (AVSC &#xB0;/s) of the patient during the
monitoring process - IPEC, FioCruz, Rio de Janeiro, 2011) show the variations
in pure tone audiometry and of the angular velocity of the slow component of
nystagmus, during the patient's follow-up.</p>
      <p>
<fig id="f01" orientation="portrait" position="float"><label>Graph 1 -</label><caption><title>Pure tone audiometry through air conduction of the left ear of a
patient during monitoring - IPEC, FioCruz, Rio de Janeiro, 2011.</title></caption><graphic xlink:href="0036-4665-rimtsp-56-05-439-gf01"/></fig>
</p>
      <p>
<fig id="f02" orientation="portrait" position="float"><label>Graph 2 -</label><caption><title>Variations of Angular Velocity of the Slow Component of Nystagmus in
degrees per second (AVSC &#xB0;/s) of the patient during
monitoring - IPEC, FioCruz, Rio de Janeiro, 2011. RE - Right Ear; LE -
Left Ear.</title></caption><graphic xlink:href="0036-4665-rimtsp-56-05-439-gf02"/></fig>
</p>
    </sec>
    <sec sec-type="discussion">
      <title>DISCUSSION</title>
      <p id="para13">We reported the first well documented case on cochlear-vestibular
toxicity related to MA diagnosed during a longitudinal study with patients with TL
submitted to vestibular and auditory evaluation when under treatment with
antimonials.</p>
      <p id="para14">The patient had been using other drugs for a long term, without dizziness
or tinnitus complaints, before beginning treatment with MA, thus we assumed that
those drugs did not influence the development of such symptoms. This hypothesis is
favored by the time factor, since the worsening of auditory thresholds, tinnitus and
dizziness started after initiating MA treatment, following a reasonable time after
drug administration, when the levels of this drug were well established in body
fluids and tissues<sup><xref rid="B07" ref-type="bibr">7</xref></sup>, and it was
confirmed because signs and symptoms improved when the treatment was discontinued,
thus showing that a relationship between these adverse effects and MA is likely to
be true. Although infection has not responded to treatment with MA, we do not
believe that the outcome of the infection may have had an influence on the MA
ototoxicity, since the disease itself would not be capable of causing the
sensorineural changes found in this patient. The success of treatment with
pentavalent antimonials depends on the peak value reached in serum or the
maintenance of a minimum inhibitory concentration in serum, during most part of the
time<sup><xref rid="B03" ref-type="bibr">3</xref></sup>. The finding that
pentavalent antimonial is rapidly excreted in the urine, resulting in sub
therapeutic serum levels in a few hours, led to the conclusion that the risk of
cumulative toxicity is low and that intermittent therapeutic schemes are
pharmacologically inconsistent<sup><xref rid="B03" ref-type="bibr">3</xref>,<xref rid="B07" ref-type="bibr">7</xref></sup>. However, <italic>in vivo</italic>
evidences of meglumine antimoniate conversion from Sb<sup>5+</sup> into
Sb<sup>3+</sup> and the accumulation of Sb<sup>3+</sup> in the tissues
suggest that Sb<sup>3+</sup> production could be responsible for the sustained
activity of the drug, both therapeutic and toxic. Just a small conversion of the
Sb<sup>5+</sup> drug seems to occur during the phase of rapid excretion,
however, it is followed by a phase of slow excretion of a high proportion of
Sb<sup>3+</sup> with a half-life of more than 50 days<sup><xref rid="B07" ref-type="bibr">7</xref></sup>. This pharmacokinetic behavior
could explain the worsening of the auditory thresholds and AVSC at 18 &#xB0;C
alterations up to 28 days after discontinuing the treatment. Additionally, the
patient had mucosal leishmaniasis which requires a treatment of 30 days with MA.
Therefore, ototoxicity could not have been so intense, if he had cutaneous
leishmaniasis which requires a shorter treatment time up to 21 days.</p>
      <p id="para15">However, the use of other ototoxic drugs may lead to more frequent
cochlear-vestibular toxicity which, in this particular case, could have been
enhanced by the use of doxazosin mesylate and hydrochlorothiazide, both potentially
ototoxic<sup><xref rid="B13" ref-type="bibr">13</xref></sup>. Non-steroidal
anti-inflammatory drugs (NSAIDs) are related to reversible ototoxicity,
with 1% to 3% incidence<sup><xref rid="B17" ref-type="bibr">17</xref></sup>. They can induce vestibular disorders, less frequent than
auditory disorders, such as tinnitus and hearing loss. The effect is more metabolic
than structural, usually reversible, and proportional to the plasma concentration of
the toxic drug. However, the patient had been using this drug for the last seventeen
years, sporadically, without reporting any audio vestibular symptom<sup><xref rid="B05" ref-type="bibr">5</xref>,<xref rid="B14" ref-type="bibr">14</xref>,<xref rid="B17" ref-type="bibr">17</xref></sup>.</p>
      <p id="para16">Our study failed in not performing high frequency audiometry, since
cochleotoxicity can occur, initially or solely, at the high frequency series from 9
to 20 kHz. Thus, the use of audiometry at conventional frequencies only, could have
hindered an earlier and/or bilateral alteration in this case study<sup><xref rid="B01" ref-type="bibr">1</xref></sup>. The role of effective monitoring
of the cochlear function in early detection of ototoxicity of DPOAE has been
reported, through drop of their responses<sup><xref rid="B18" ref-type="bibr">18</xref></sup>. In this patient, this assessment was hampered because the
DPOAE were already absent at the beginning of treatment. However, the evolution of
the reported case was documented through serial examinations<sup><xref rid="B16" ref-type="bibr">16</xref></sup>.</p>
      <p id="para17">The occurrence of subclinical ototoxicity of some drugs<sup><xref rid="B01" ref-type="bibr">1</xref></sup> diagnosed by audiometry control has
been described. To our knowledge, this is the first controlled case study of
ototoxicity related to MA. This explains the fact that we could not find in
literature references of hearing loss caused by this drug.</p>
      <p id="para18">The most frequently reported adverse effects of pentavalent antimonials
were musculoskeletal pain, gastrointestinal disturbances, mild to moderate headache,
electrocardiographic QTc interval prolongation, mild to moderate increase in liver
and pancreatic enzymes and significant suppression of mean lymphocyte and platelet
counts<sup><xref rid="B11" ref-type="bibr">11</xref>,<xref rid="B19" ref-type="bibr">19</xref></sup>. However, cochlear-vestibular toxicity is not
frequently reported. Tinnitus and dizziness had already been reported during ML
treatment with tartar emetic<sup><xref rid="B09" ref-type="bibr">9</xref></sup>.
Considering a recent report stating that Sb<sup>3+</sup> levels represent more
than 30% of total Sb concentrations in Glucantime&#xAE;, we can suppose that
Glucantime&#xAE; may not be so different from trivalent antimonial tartar emetic and
that Sb<sup>3+</sup> may account for its ototoxicity<sup><xref rid="B15" ref-type="bibr">15</xref></sup>. The patient studied in the present case was a
senior, male, and presented renal, hepatic and pancreatic toxicity. Dizziness
associated to the use of meglumine antimoniate has already been reported regarding
females, aged 60 years or more and related to pancreatic toxicity<sup><xref rid="B02" ref-type="bibr">2</xref></sup>. Because of its toxicity, meglumine
antimoniate should be used with caution in patients older than 60 years<sup><xref rid="B08" ref-type="bibr">8</xref></sup>.</p>
      <p id="para19">As for vestibular toxicity, the most common finding is hyporeflex or
simply normal reflex associated to vestibular complaints of the patient. Besides, it
has been described that a reduction of 50% or more of the vestibular system, in
at least one ear, indicates vestibular toxicity<sup><xref rid="B10" ref-type="bibr">10</xref></sup>. Although all the examinations of this case presented AVSC
at 18 &#xB0;C within normal reflex values, it is evident that a reduction of more
than 50% of this value occurred from the beginning of symptoms to 16 days after
treatment, and that, a year later, the patient being asymptomatic, there was a
return to values similar to the beginning of symptoms. Unfortunately, we do not have
values before treatment to compare. Apparently tinnitus and dizziness are not
related, since time of maximum tinnitus alteration did not correspond to that of
maximum dizziness.</p>
      <p id="para20">At the end of the ongoing longitudinal study, we intend to clarify some
aspects related to the ototoxicity of meglumine antimoniate, such as dose
dependence, relation with treatment duration, reversibility or not, as well as the
associated risk factors.</p>
    </sec>
  </body>
  <back>
    <ack>
      <title>ACKNOWLEDGMENTS</title>
      <p id="para21">The authors would like to thank Maria In&#xEA;s Fernandes Pimentel and
&#xC9;rica Camargo de Vasconcellos.</p>
      <p id="para22">This study had the financial support of FAPERJ and CNPQ to buy the
audio-vestibulometry equipment and in the form of scholarships of scientific
initiation and PQ CNPq and FAPERJ Our State Scientist, master, doctors etc.</p>
      <p id="para23">The authors state no conflict of interest.</p>
      <p id="para24">Cl&#xE1;udia Maria Valete-Rosalino has full access to all the data in the
study and takes responsibility for their integrity.</p>
    </ack>
    <ref-list>
      <title>REFERENCES</title>
      <ref id="B01">
        <label>1</label>
        <element-citation publication-type="journal">
          <person-group person-group-type="author">
            <collab>American Speech-Language-Hearing Association</collab>
          </person-group>
          <article-title>Guidelines: audiologic management of individuals
receiving cochleotoxic drug therapy</article-title>
          <source>Practice Policy. ASHA</source>
          <year>1994</year>
          <volume>36</volume>
          <fpage>11</fpage>
          <lpage>9</lpage>
        </element-citation>
      </ref>
      <ref id="B02">
        <label>2</label>
        <element-citation publication-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Araujo-Melo</surname>
              <given-names>MH</given-names>
            </name>
            <name>
              <surname>Meneses</surname>
              <given-names>AM</given-names>
            </name>
            <name>
              <surname>Schubach</surname>
              <given-names>AO</given-names>
            </name>
            <name>
              <surname>Moreira</surname>
              <given-names>JS</given-names>
            </name>
            <name>
              <surname>Concei&#xE7;&#xE3;o-Silva</surname>
              <given-names>F</given-names>
            </name>
            <name>
              <surname>Salgueiro</surname>
              <given-names>MM</given-names>
            </name>
            <etal/>
          </person-group>
          <article-title>Risk factors associated to dizziness during
treatment for mucosal leishmaniasis with meglumine antimoniate: 16-year
retrospective study of cases from Rio de Janeiro, Brazil</article-title>
          <source>J Laryngol Otol</source>
          <year>2010</year>
          <volume>124</volume>
          <fpage>1056</fpage>
          <lpage>60</lpage>
          <pub-id pub-id-type="pmid">20537206</pub-id>
        </element-citation>
      </ref>
      <ref id="B03">
        <label>3</label>
        <element-citation publication-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Chulay</surname>
              <given-names>JD</given-names>
            </name>
            <name>
              <surname>Fleckenstein</surname>
              <given-names>G</given-names>
            </name>
            <name>
              <surname>Smith</surname>
              <given-names>DH</given-names>
            </name>
          </person-group>
          <article-title>Pharmacokinetics of antimony during treatment of
visceral leishmaniasis with sodium stibogluconate or meglumine
antimoniate</article-title>
          <source>Trans R Soc Trop Med Hyg</source>
          <year>1988</year>
          <volume>82</volume>
          <fpage>69</fpage>
          <lpage>72</lpage>
          <pub-id pub-id-type="pmid">2845611</pub-id>
        </element-citation>
      </ref>
      <ref id="B04">
        <label>4</label>
        <element-citation publication-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>de Camargo Ferreira e Vasconcellos</surname>
              <given-names>E</given-names>
            </name>
            <name>
              <surname>Schubach</surname>
              <given-names>AO</given-names>
            </name>
            <name>
              <surname>Valete-Rosalino</surname>
              <given-names>CM</given-names>
            </name>
            <name>
              <surname>Coutinho</surname>
              <given-names>RS</given-names>
            </name>
            <name>
              <surname>Concei&#xE7;&#xE3;o-Silva</surname>
              <given-names>F</given-names>
            </name>
            <name>
              <surname>Salgueiro</surname>
              <given-names>MM</given-names>
            </name>
            <etal/>
          </person-group>
          <article-title>American tegumentary leishmaniasis in older adults:
44 cases treated with an intermittent low-dose antimonial schedule in Rio de
Janeiro, Brazil</article-title>
          <source>J Am Geriatr Soc</source>
          <year>2010</year>
          <volume>58</volume>
          <fpage>614</fpage>
          <lpage>6</lpage>
          <pub-id pub-id-type="pmid">20398135</pub-id>
        </element-citation>
      </ref>
      <ref id="B05">
        <label>5</label>
        <element-citation publication-type="book">
          <person-group person-group-type="author">
            <name>
              <surname>Dukes</surname>
              <given-names>MNG</given-names>
            </name>
            <name>
              <surname>Aronson</surname>
              <given-names>JK</given-names>
            </name>
          </person-group>
          <article-title>Meyler's side effects of drugs</article-title>
          <edition>14th ed</edition>
          <publisher-loc>Amsterdan</publisher-loc>
          <publisher-name>Elsevier</publisher-name>
          <year>2000</year>
        </element-citation>
      </ref>
      <ref id="B06">
        <label>6</label>
        <element-citation publication-type="book">
          <person-group person-group-type="author">
            <name>
              <surname>Lima</surname>
              <given-names>MLLT</given-names>
            </name>
          </person-group>
          <article-title>Tratamento para tuberculose com estreptomicina:
perfil auditivo e vestibular</article-title>
          <comment>[disserta&#xE7;&#xE3;o]</comment>
          <publisher-loc>Recife</publisher-loc>
          <publisher-name>Centro de Pesquisas Aggeu Magalh&#xE3;es,
FIOCRUZ</publisher-name>
          <year>2003</year>
        </element-citation>
      </ref>
      <ref id="B07">
        <label>7</label>
        <element-citation publication-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Miekeley</surname>
              <given-names>N</given-names>
            </name>
            <name>
              <surname>Mortari</surname>
              <given-names>SR</given-names>
            </name>
            <name>
              <surname>Schubach</surname>
              <given-names>AO</given-names>
            </name>
          </person-group>
          <article-title>Monitoring of total antimony and its species by
ICP-MS and on-line ion chromatography in biological samples from patients
treated for leishmaniasis</article-title>
          <source>Anal Bioanal Chem</source>
          <year>2002</year>
          <volume>372</volume>
          <fpage>495</fpage>
          <lpage>502</lpage>
          <pub-id pub-id-type="pmid">11939540</pub-id>
        </element-citation>
      </ref>
      <ref id="B08">
        <label>8</label>
        <element-citation publication-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Mosimann</surname>
              <given-names>V</given-names>
            </name>
            <name>
              <surname>Neumayr</surname>
              <given-names>A</given-names>
            </name>
            <name>
              <surname>Hartz</surname>
              <given-names>C</given-names>
            </name>
            <name>
              <surname>Blum</surname>
              <given-names>JA</given-names>
            </name>
          </person-group>
          <article-title>Cutaneous leishmaniasis in Switzerland: first
experience with species-specific treatment</article-title>
          <source>Infection</source>
          <year>2013</year>
          <volume>41</volume>
          <fpage>1177</fpage>
          <lpage>82</lpage>
          <pub-id pub-id-type="pmid">23835701</pub-id>
        </element-citation>
      </ref>
      <ref id="B09">
        <label>9</label>
        <element-citation publication-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Nery-Guimar&#xE3;es</surname>
              <given-names>F</given-names>
            </name>
          </person-group>
          <article-title>Estudo de um foco de leishmaniose muco-cut&#xE2;nea
na Baixada Fluminense (Estado do Rio de Janeiro)</article-title>
          <source>Mem Inst Oswaldo Cruz</source>
          <year>1955</year>
          <volume>53</volume>
          <fpage>1</fpage>
          <lpage>11</lpage>
          <pub-id pub-id-type="pmid">13265230</pub-id>
        </element-citation>
      </ref>
      <ref id="B10">
        <label>10</label>
        <element-citation publication-type="book">
          <person-group person-group-type="author">
            <name>
              <surname>Oliveira</surname>
              <given-names>JAA</given-names>
            </name>
          </person-group>
          <article-title>Ototoxicidade</article-title>
          <person-group person-group-type="editor">
            <name>
              <surname>Costa</surname>
              <given-names>SS</given-names>
            </name>
            <name>
              <surname>Cruz</surname>
              <given-names>OLM</given-names>
            </name>
            <name>
              <surname>Oliveira</surname>
              <given-names>JAA</given-names>
            </name>
          </person-group>
          <source>Otorrinolaringologia: princ&#xED;pios e
pr&#xE1;tica</source>
          <publisher-loc>Porto Alegre</publisher-loc>
          <publisher-name>Artes M&#xE9;dicas</publisher-name>
          <year>1994</year>
          <fpage>217</fpage>
        </element-citation>
      </ref>
      <ref id="B11">
        <label>11</label>
        <element-citation publication-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Oliveira</surname>
              <given-names>LF</given-names>
            </name>
            <name>
              <surname>Schubach</surname>
              <given-names>AO</given-names>
            </name>
            <name>
              <surname>Martins</surname>
              <given-names>MM</given-names>
            </name>
            <name>
              <surname>Passos</surname>
              <given-names>SL</given-names>
            </name>
            <name>
              <surname>Oliveira</surname>
              <given-names>RV</given-names>
            </name>
            <name>
              <surname>Marzochi</surname>
              <given-names>MC</given-names>
            </name>
            <etal/>
          </person-group>
          <article-title>Systematic review of the adverse effects of
cutaneous leishmaniasis treatment in the New World</article-title>
          <source>Acta Trop</source>
          <year>2011</year>
          <volume>118</volume>
          <fpage>87</fpage>
          <lpage>96</lpage>
          <pub-id pub-id-type="pmid">21420925</pub-id>
        </element-citation>
      </ref>
      <ref id="B12">
        <label>12</label>
        <element-citation publication-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Passos</surname>
              <given-names>VM</given-names>
            </name>
            <name>
              <surname>Barreto</surname>
              <given-names>SM</given-names>
            </name>
            <name>
              <surname>Romanha</surname>
              <given-names>AJ</given-names>
            </name>
            <name>
              <surname>Krettli</surname>
              <given-names>AU</given-names>
            </name>
            <name>
              <surname>Volpini</surname>
              <given-names>AC</given-names>
            </name>
            <name>
              <surname>Gontijo</surname>
              <given-names>CM</given-names>
            </name>
            <etal/>
          </person-group>
          <article-title>Cutaneous leishmaniasis in the metropolitan region
of Belo Horizonte: clinical, laboratorial, therapeutic and prognosis
features (1989-1995)</article-title>
          <source>Rev Soc Bras Med Trop</source>
          <year>2001</year>
          <volume>34</volume>
          <fpage>5</fpage>
          <lpage>12</lpage>
          <pub-id pub-id-type="pmid">11340491</pub-id>
        </element-citation>
      </ref>
      <ref id="B13">
        <label>13</label>
        <element-citation publication-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Picon</surname>
              <given-names>PD</given-names>
            </name>
            <name>
              <surname>Della Giustina</surname>
              <given-names>ML</given-names>
            </name>
            <name>
              <surname>Rizzon</surname>
              <given-names>CFC</given-names>
            </name>
            <name>
              <surname>Bassanesi</surname>
              <given-names>SL</given-names>
            </name>
            <name>
              <surname>Zanardo</surname>
              <given-names>AP</given-names>
            </name>
            <name>
              <surname>Michalczuk</surname>
              <given-names>MT</given-names>
            </name>
            <etal/>
          </person-group>
          <article-title>Resultado do tratamento da tuberculose com
estreptomicina, isoniazida e etambutol (esquema
SHM)</article-title>
          <source>J Bras Pneumol</source>
          <year>2002</year>
          <volume>28</volume>
          <fpage>187</fpage>
          <lpage>92</lpage>
        </element-citation>
      </ref>
      <ref id="B14">
        <label>14</label>
        <element-citation publication-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Rascol</surname>
              <given-names>O</given-names>
            </name>
            <name>
              <surname>Hain</surname>
              <given-names>TC</given-names>
            </name>
            <name>
              <surname>Brefel</surname>
              <given-names>C</given-names>
            </name>
            <name>
              <surname>Benazet</surname>
              <given-names>M</given-names>
            </name>
            <name>
              <surname>Clanet</surname>
              <given-names>M</given-names>
            </name>
            <name>
              <surname>Montastruc</surname>
              <given-names>J</given-names>
            </name>
          </person-group>
          <article-title>Antivertigo medications and drug-induced vertigo. A
pharmacological review</article-title>
          <source>Drugs</source>
          <year>1995</year>
          <volume>50</volume>
          <fpage>777</fpage>
          <lpage>91</lpage>
          <pub-id pub-id-type="pmid">8586026</pub-id>
        </element-citation>
      </ref>
      <ref id="B15">
        <label>15</label>
        <element-citation publication-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Sala&#xFC;n</surname>
              <given-names>P</given-names>
            </name>
            <name>
              <surname>Fr&#xE9;zard</surname>
              <given-names>F</given-names>
            </name>
          </person-group>
          <article-title>Unexpectedly high levels of antimony
(III) in the pentavalent antimonial drug glucantime: insights from
a new voltammetric approach</article-title>
          <source>Anal Bioanal Chem</source>
          <year>2013</year>
          <volume>405</volume>
          <fpage>5201</fpage>
          <lpage>14</lpage>
          <pub-id pub-id-type="pmid">23612869</pub-id>
        </element-citation>
      </ref>
      <ref id="B16">
        <label>16</label>
        <element-citation publication-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Santos</surname>
              <given-names>CF</given-names>
            </name>
            <name>
              <surname>Valete</surname>
              <given-names>CM</given-names>
            </name>
            <name>
              <surname>Martins</surname>
              <given-names>AG</given-names>
            </name>
            <collab>Ferreira</collab>
            <collab>NGM</collab>
            <name>
              <surname>Tomita</surname>
              <given-names>S</given-names>
            </name>
          </person-group>
          <article-title>Clinical aspects of ototoxicity of
aminiglicosideos</article-title>
          <source>Acta ORL</source>
          <year>2000</year>
          <volume>19</volume>
          <fpage>160</fpage>
          <lpage>4</lpage>
        </element-citation>
      </ref>
      <ref id="B17">
        <label>17</label>
        <element-citation publication-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Seligmann</surname>
              <given-names>H</given-names>
            </name>
            <name>
              <surname>Podoshin</surname>
              <given-names>L</given-names>
            </name>
            <name>
              <surname>Ben-David</surname>
              <given-names>J</given-names>
            </name>
            <name>
              <surname>Fradis</surname>
              <given-names>M</given-names>
            </name>
            <name>
              <surname>Goldsher</surname>
              <given-names>M</given-names>
            </name>
          </person-group>
          <article-title>Drug-induced tinnitus and other hearing
disorders</article-title>
          <source>Drug Saf</source>
          <year>1996</year>
          <volume>14</volume>
          <fpage>198</fpage>
          <lpage>212</lpage>
          <pub-id pub-id-type="pmid">8934581</pub-id>
        </element-citation>
      </ref>
      <ref id="B18">
        <label>18</label>
        <element-citation publication-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Vallejo</surname>
              <given-names>JC</given-names>
            </name>
            <name>
              <surname>Silva</surname>
              <given-names>MN</given-names>
            </name>
            <name>
              <surname>Oliveira</surname>
              <given-names>JAA</given-names>
            </name>
            <name>
              <surname>Carneiro</surname>
              <given-names>JJ</given-names>
            </name>
            <name>
              <surname>Rocha</surname>
              <given-names>LSO</given-names>
            </name>
            <name>
              <surname>Figueiredo</surname>
              <given-names>JFC</given-names>
            </name>
            <etal/>
          </person-group>
          <article-title>Detec&#xE7;&#xE3;o precoce de ototoxicidade usando
emiss&#xF5;es otoac&#xFA;sticas produtivas de
distor&#xE7;&#xE3;o</article-title>
          <source>Braz J Otorhinolaryngol</source>
          <year>2001</year>
          <volume>67</volume>
          <fpage>845</fpage>
          <lpage>51</lpage>
        </element-citation>
      </ref>
      <ref id="B19">
        <label>19</label>
        <element-citation publication-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Wise</surname>
              <given-names>ES</given-names>
            </name>
            <name>
              <surname>Armstrong</surname>
              <given-names>MS</given-names>
            </name>
            <name>
              <surname>Watson</surname>
              <given-names>J</given-names>
            </name>
            <name>
              <surname>Lockwood</surname>
              <given-names>DN</given-names>
            </name>
          </person-group>
          <article-title>Monitoring toxicity associated with parenteral
sodium stibogluconate in the day-case management of returned travellers with
New World cutaneous leishmaniasis</article-title>
          <source>Plos Negl Trop Dis</source>
          <year>2012</year>
          <volume>6</volume>
          <issue>(6)</issue>
          <elocation-id/>
        </element-citation>
      </ref>
    </ref-list>
  </back>
</article>
</pmc-articleset>
